|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTIF2 |
Gene summary for MTIF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTIF2 | Gene ID | 4528 |
| Gene name | mitochondrial translational initiation factor 2 | |
| Gene Alias | MTIF2 | |
| Cytomap | 2p16.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P46199 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4528 | MTIF2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.16e-12 | 5.42e-01 | -0.1954 |
| 4528 | MTIF2 | A015-C-203 | Human | Colorectum | FAP | 2.71e-08 | 1.02e-02 | -0.1294 |
| 4528 | MTIF2 | A001-C-108 | Human | Colorectum | FAP | 3.54e-03 | 1.12e-01 | -0.0272 |
| 4528 | MTIF2 | A002-C-205 | Human | Colorectum | FAP | 6.12e-03 | 6.08e-02 | -0.1236 |
| 4528 | MTIF2 | A015-C-006 | Human | Colorectum | FAP | 8.65e-04 | 2.74e-01 | -0.0994 |
| 4528 | MTIF2 | A002-C-114 | Human | Colorectum | FAP | 1.81e-02 | 1.49e-01 | -0.1561 |
| 4528 | MTIF2 | A015-C-104 | Human | Colorectum | FAP | 4.03e-09 | 7.33e-02 | -0.1899 |
| 4528 | MTIF2 | A002-C-016 | Human | Colorectum | FAP | 3.54e-04 | 4.46e-03 | 0.0521 |
| 4528 | MTIF2 | A002-C-116 | Human | Colorectum | FAP | 5.31e-09 | -9.12e-02 | -0.0452 |
| 4528 | MTIF2 | A018-E-020 | Human | Colorectum | FAP | 9.22e-03 | -3.95e-02 | -0.2034 |
| 4528 | MTIF2 | F034 | Human | Colorectum | FAP | 1.09e-03 | 6.92e-02 | -0.0665 |
| 4528 | MTIF2 | CRC-1-8810 | Human | Colorectum | CRC | 3.60e-03 | -8.54e-02 | 0.6257 |
| 4528 | MTIF2 | CRC-3-11773 | Human | Colorectum | CRC | 3.18e-02 | -7.31e-02 | 0.2564 |
| 4528 | MTIF2 | LZE2T | Human | Esophagus | ESCC | 1.76e-04 | 4.44e-01 | 0.082 |
| 4528 | MTIF2 | LZE4T | Human | Esophagus | ESCC | 1.65e-13 | 2.83e-01 | 0.0811 |
| 4528 | MTIF2 | LZE8T | Human | Esophagus | ESCC | 4.69e-02 | 5.11e-02 | 0.067 |
| 4528 | MTIF2 | LZE24T | Human | Esophagus | ESCC | 1.77e-10 | 3.03e-01 | 0.0596 |
| 4528 | MTIF2 | LZE6T | Human | Esophagus | ESCC | 5.80e-03 | 1.02e-01 | 0.0845 |
| 4528 | MTIF2 | P1T-E | Human | Esophagus | ESCC | 4.56e-05 | 3.45e-01 | 0.0875 |
| 4528 | MTIF2 | P2T-E | Human | Esophagus | ESCC | 5.35e-25 | 5.30e-01 | 0.1177 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:1903008 | Colorectum | AD | organelle disassembly | 46/3918 | 114/18723 | 1.81e-06 | 5.48e-05 | 46 |
| GO:0006413 | Colorectum | AD | translational initiation | 45/3918 | 118/18723 | 1.35e-05 | 2.92e-04 | 45 |
| GO:0006446 | Colorectum | AD | regulation of translational initiation | 28/3918 | 79/18723 | 2.02e-03 | 1.63e-02 | 28 |
| GO:00064174 | Colorectum | FAP | regulation of translation | 111/2622 | 468/18723 | 8.47e-09 | 1.13e-06 | 111 |
| GO:00224114 | Colorectum | FAP | cellular component disassembly | 97/2622 | 443/18723 | 3.44e-06 | 1.23e-04 | 97 |
| GO:00064463 | Colorectum | FAP | regulation of translational initiation | 26/2622 | 79/18723 | 1.54e-05 | 4.01e-04 | 26 |
| GO:00064134 | Colorectum | FAP | translational initiation | 34/2622 | 118/18723 | 2.13e-05 | 5.12e-04 | 34 |
| GO:19030083 | Colorectum | FAP | organelle disassembly | 30/2622 | 114/18723 | 3.71e-04 | 4.63e-03 | 30 |
| GO:00064175 | Colorectum | CRC | regulation of translation | 82/2078 | 468/18723 | 1.79e-05 | 5.40e-04 | 82 |
| GO:00224115 | Colorectum | CRC | cellular component disassembly | 75/2078 | 443/18723 | 1.26e-04 | 2.42e-03 | 75 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTIF2 | SNV | Missense_Mutation | c.732G>A | p.Met244Ile | p.M244I | P46199 | protein_coding | tolerated(0.06) | possibly_damaging(0.606) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MTIF2 | SNV | Missense_Mutation | novel | c.1741N>A | p.Val581Ile | p.V581I | P46199 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| MTIF2 | SNV | Missense_Mutation | c.219N>C | p.Lys73Asn | p.K73N | P46199 | protein_coding | deleterious(0.04) | benign(0.255) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MTIF2 | SNV | Missense_Mutation | c.2044N>A | p.Asp682Asn | p.D682N | P46199 | protein_coding | deleterious(0.04) | benign(0.051) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTIF2 | SNV | Missense_Mutation | novel | c.1006G>A | p.Glu336Lys | p.E336K | P46199 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| MTIF2 | deletion | In_Frame_Del | c.2128_2130delNNN | p.Val710del | p.V710del | P46199 | protein_coding | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |||
| MTIF2 | SNV | Missense_Mutation | novel | c.1151G>T | p.Gly384Val | p.G384V | P46199 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTIF2 | SNV | Missense_Mutation | novel | c.1057G>A | p.Gly353Ser | p.G353S | P46199 | protein_coding | deleterious(0.02) | probably_damaging(0.92) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTIF2 | SNV | Missense_Mutation | novel | c.172C>A | p.Leu58Ile | p.L58I | P46199 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTIF2 | SNV | Missense_Mutation | novel | c.441N>A | p.Met147Ile | p.M147I | P46199 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |